acalabrutinibacuteadultsadvancedallogeneicamlanalysisasctavdaxicabtagenebendamustinebestbonebortezomibcarecellchronicciloleucelclassiccomparedcontrolledcorticosteroidcyclophosphamidecytarabinedaratumumabdecitabinedexamethasonediagnoseddiffusediseasedonordonorsdosedoubleduplicationdurationfinalfirstfixedflt3followgilteritinibgraftguidedhaploidenticalhematopoietichighhlahodgkinhosthsctibrutinibiiiimmunochemotherapyinductioninfusioninternallabellargelenalidomideleukemialonglowlymphoblasticlymphocyticlymphomamaintenancemantlemarrowmatchedmethotrexatemrdmulticentermulticentremultiplemutationmycophenolatemyelodysplasticmyeloidmyelomanewlynivolumabolderopenoraloutcomespatientsphaseplacebopluspomalidomidepostposttransplantposttransplantationpreventionprophylacticprophylaxisptcyrandomisedrandomizedreducedrefractoryrelapsedremissionresidualresultsriskrituximabruxolitinibstagestandardstemstudysubcutaneoussyndrometacrolimustandemtermtherapytransplanttransplantationtreatedtrialunrelateduntreatedvenetoclaxversuswithoutzanubrutinib